BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive COVID-19 vaccine approval in Europe was reassuring for a ...
“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This ...
Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:ARCT), expressing a variety of opinions spanning from bullish to bearish. The table below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback